The manufacturer Moderna has started its first clinical study to investigate a corona vaccine specially tailored to the omicron variant. A total of 600 volunteers – some with two or three injections – would take part at 24 locations in the United States, Moderna announced on Wednesday (local time).
SN/APA/AFP/JULIO CESAR AGUILAR
Vaccine specifically matched to Omicron is being tested
The resistance of the antibodies with the normal booster vaccination is optimistic, said Moderna boss Stéphane Bancel. “Nevertheless, given the long-term threat of the so-called Omicron immune escape, we continue to advance our Omicron-specific vaccine candidate.”
Recently, Biontech and Pfizer also announced the testing of their vaccine candidate against Omikron. Safety, tolerability and effectiveness are to be checked, as the two companies announced on Tuesday. The study will include up to 1,420 test subjects who will be divided into three groups.
Meanwhile, the specialist journal “New England Journal of Medicine” published an investigation into the effectiveness of Moderna’s previously approved booster against the omicron variant. Accordingly, the antibody level against the highly contagious mutation of the coronavirus is 20 times higher one month after the third injection than after the second – but it decreases significantly in the months that follow.
Accessed on January 27, 2022 at 1:15 am at https://www.sn.at/panorama/international/moderna-startet-klische-studie-zu-omikron-impfstoff-116120149